Compare Revvity Inc (RVTY) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Xpeng Inc - ADR — how do they compare? Revvity Inc trades at $124.14 (market cap $14.18B), while Xpeng Inc - ADR trades at $10.63 (market cap $10.34B). The key difference: Revvity Inc is the larger of the two by market cap, and Revvity Inc pays a 0.22% dividend while Xpeng Inc - ADR pays none. Which is the better fit depends on your goals.
| RVTY | XPEV | |
|---|---|---|
Market Cap | $14.18B | $10.34B |
Sector | Technology | Consumer Cyclical |
52-Week High | $130.94 | $28.07 |
52-Week Low | $82.26 | $10.57 |
Enterprise Value | $16.50B | $12.92B |
Dividend Yield | 0.22% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $127.08, down 2.41% on the day, with a bullish technical signal from moving averages and strong support at $126. The company reported Q2 2026 EPS of $1.41, beating estimates, and raised its full-year outlook, driven by diagnostics strength and improved cash flow. Recent news includes the acquisition of Human Cell Design and the launch of the SuperFlex prenatal screening system.
Outlook is positive with 52% analyst buy ratings and a $135.25 consensus price target, implying ~6% upside. Risks include a premium valuation (P/E 61.1) and execution of growth initiatives. Strong institutional interest, such as Bank of New York Mellon's $78.77 million investment, supports confidence in the stock's trajectory.
XPEV trades at $10.93, down 0.18% for the day, with a bearish technical signal from moving averages. The company reported a net loss of $1.14B in 2025 despite revenue growth to $76.72B, and recent quarterly earnings missed expectations. Positive developments include a $900M robotics unit funding at a $6.3B valuation and new model launches aimed at boosting deliveries.
The outlook remains cautious due to persistent losses and competitive pressures, but analyst consensus is bullish with a $19 price target. Key risks include execution challenges in EV and robotics segments, while institutional interest and AI-driven initiatives offer potential upside if profitability improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
